Jasper Ridge Partners’s Nurix Therapeutics NRIX Stock Holding History

Jasper Ridge Partners’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Hold	95,711	–	–	0.03%	77
2025 Q4	$1.82M	Hold	95,711	–	–	0.04%	75
2025 Q3	$884K	Hold	95,711	–	–	0.02%	92
2025 Q2	$1.09M	Hold	95,711	–	–	0.03%	87
2025 Q1	$1.14M	Hold	95,711	–	–	0.04%	80
2024 Q4	$1.8M	Hold	95,711	–	–	0.06%	72
2024 Q3	$2.15M	Hold	95,711	–	–	0.06%	72
2024 Q2	$2M	Hold	95,711	–	–	0.06%	76
2024 Q1	$1.41M	Hold	95,711	–	–	0.04%	87
2023 Q4	$988K	Hold	95,711	–	–	0.04%	85
2023 Q3	$752K	Hold	95,711	–	–	0.04%	89
2023 Q2	$956K	Hold	95,711	–	–	0.05%	79
2023 Q1	$850K	Hold	95,711	–	–	0.04%	89
2022 Q4	$1.05M	Hold	95,711	–	–	0.06%	77
2022 Q3	$1.25M	Sell	95,711 -2,976	-3%	-$47.1K	0.08%	73
2022 Q2	$1.25M	Hold	98,687	–	–	0.08%	75
2022 Q1	$1.38M	Hold	98,687	–	–	0.07%	79
2021 Q4	$2.86M	Buy	98,687 +2,976	+3%	+$90.2K	0.11%	69
2021 Q3	$2.87M	Sell	95,711 -84,769	-47%	-$2.62M	0.13%	71
2021 Q2	$4.79M	Buy	180,480 +146,994	+439%	+$4.32M	0.24%	50
2021 Q1	$1.04M	Buy	+33,486	New	+$1.27M	0.05%	84

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jasper Ridge Partners's NRIX Position: Q1 2026 in Review

Jasper Ridge Partners held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 95,711 shares worth $1.48M. The position accounts for 0.03% of the portfolio, ranked #77.

Jasper Ridge Partners first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $4.79M in Q2 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Jasper Ridge Partners held 95,711 shares of Nurix Therapeutics worth $1.48M as of Q1 2026.
Jasper Ridge Partners left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up 0.03% of Jasper Ridge Partners's portfolio in Q1 2026, its #77 holding.
Jasper Ridge Partners first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
Jasper Ridge Partners's Nurix Therapeutics position peaked at $4.79M in Q2 2021.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Jasper Ridge Partners's 13F filing for Q1 2026, filed 11 May 2026.